MétaCan
Menu
Back to cohort

716 A randomized phase II window of opportunity clinical trial of PD-1 +/- IL-4 inhibition in early-stage ER+ HER2- breast cancer

2024· article· en· W4404053084 on OpenAlexaffabout
Angel Arnaout, Megan Hopkins, Oleg Saldaña, Vanessa Lopez Ozuna, Vida Talebian, Drashti Jain, Gregory R. Pond, Teresa Petrocelli, Melanie Spears

Bibliographic record

VenueRegular and Young Investigator Award Abstracts · 2024
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsOttawa HospitalMcMaster UniversityOntario Institute for Cancer Research
Fundersnot available
KeywordsBreast cancerStage (stratigraphy)OncologyWindow of opportunityWindow (computing)Internal medicineMedicineCancerComputer scienceBiologyReal-time computing

Abstract

fetched live from OpenAlex

<h3>Background</h3> Immune checkpoint inhibition has been shown to enhance response to neoadjuvant therapy and survival in triple negative breast cancer (BC). However, the majority of BCs are estrogen receptor positive (ER+), which is traditionally considered to be immunologically cold, with low expression of PD-L1, decreased tumour mutational burden, and reduced neoantigen presentation. Window of Opportunity (WOO) trial designs support rapid evaluation of therapeutic combinations and predict effectiveness in larger neoadjuvant trials. We conducted a WOO trial in ER+ BC patients to determine whether the response to immune checkpoint inhibitors (cemiplimab, a PD-1 inhibitor) within the tumor could be enhanced by the addition of IL-4R antagonist (dupilumab). <h3>Methods</h3> Female preoperative patients with newly diagnosed primary invasive T1/T2 ER+Her2- BC were randomized 1:1 to a single dose of cemiplimab (350mg IV) or in combination +/- dupilumab (600mg sc). Pre-(baseline biopsy) and post- treatment (surgical resection one week later) tissue were profiled through targeted multi-omic profiling and sequencing (DNA and RNA) spatial proteomics (NanoString’s GeoMx) and TCR sequencing. <h3>Results</h3> 20 patients were successfully recruited on the trial, 10 in each arm. Mean patient age was 61.5 years and average tumor size was 2.5cm. Most adverse events were grade 1, most commonly fatigue which was equally present in both arms. In 40 pre-treatment biopsies profiled with OCAPlus, the most frequently mutated genes included PIK3CA (25%), TP53 (23%), CDH1 (25%) and KMT2C (20%). Frequent copy number changes were identified in CCND1 (20%), FGF19 (20%), and FGF4 (20%). In the combination arm, differential gene expression and subsequent pathway analysis of enriched genes demonstrated enhanced interferon signaling, antigen presentation and processing pathways; while proteomic profiling showed only minimal changes in immune cell composition. <h3>Conclusions</h3> This WOO trial has demonstrated immunogenic effects of combining immune checkpoint inhibitors with IL-4 antagonists in ER+ BC. These findings support further exploration of this therapeutic strategy in larger neoadjuvant clinical trials aimed at improving immunotherapy responses in immunologically cold tumors. <h3>Trial Registration</h3> NCT05967884. <h3>Ethics Approval</h3> The study was approved by Clinical Trials Ontario Streamlined Research Ethics Review System, approval number 4510.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.043
Threshold uncertainty score0.774

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.046
GPT teacher head0.350
Teacher spread0.304 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueRegular and Young Investigator Award AbstractsSame topicCancer Immunotherapy and BiomarkersFrench-language works237,207